Acceleron Pharma Inc., of Cambridge, Mass., appointed James Desiderio vice president, program management.
Adolor Corp., of Exton, Pa., elected Georges Gemayel to its board.
Advancis Pharmaceutical Corp., of Germantown, Md., appointed Martin Vogelbaum to its board.
Allos Therapeutics Inc., of Westminster, Colo., appointed Jeffrey Latts to its board.
Axon Labs Inc., of Providence, R.I., appointed David Dickinson CEO and board member.
Bionovo Inc., of Emeryville, Calif., appointed Mimi Hancock to its board.
Curidium Medica plc, of London, appointed Gosse Bruinsma an executive director and executive chairman, subject to shareholder approval. Phyllis Whiteley was appointed a nonexecutive director.
Diamics Inc., of Novato, Calif., named Mitchell Golbus chief medical and technical officer.
Diffusion Pharmaceuticals LLC, of Charlottesville, Va., formed a scientific advisory board consisting of John Gainer, Stuart Grossman, John Jane and David Longnecker.
Dyax Corp., of Cambridge, Mass., is hiring Gustav Christensen as executive vice president and chief business officer.
Genelabs Technologies Inc., of Redwood City, Calif., appointed Leslie Browne and Matthew Pfeffer to its board.
ImClone Systems Inc., of New York, appointed Andrew Bonfield to its board.
ImmunoGen Inc., of Cambridge, Mass., added Stephen McCluski to its board.
IR BioSciences Holdings Inc., of Scottsdale, Ariz., appointed Robert Hariri to its board.
Keryx Biopharmaceuticals Inc., of New York, hired Beth Levine as senior vice president, general counsel and chief compliance officer. It also appointed Kevin Cameron to its board.